http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오상훈(Oh, Sang Hoon) 민족미학회 2011 민족미학 Vol.10 No.2
It is presumed that the concept of time in traditional China contrast with that of western classics such as Aristotle, and Newton. Whereas the concept of the latter could be supposed as linear and physical, the concept of time in ancient China could be non-linear and natural. In this sense, the concept of time in traditional China is inherent. And this concept of time has peculiarity too, because it is casually fused with the dimension of space. Especially, its influence is significant in the various areas of Chinese traditional culture and thought in terms of its reflection on their motives and context, for example, in Nan k"o tai shou tien(南柯太守傳), the anecdote of Chao yen(趙顔), the anecdote of Hsu Yen(許彦), Double screens(重屛) of Sung-ming period, hand scroll(畵卷) and pavilion(庭園) culture of Sung-ming period. So it is not necessary to say that it has important meaning in the Chinese art and thought anymore.
Protein Disorder Prediction Using Multilayer Perceptrons
Oh, Sang-Hoon The Korea Contents Association 2013 International Journal of Contents Vol.9 No.4
"Protein Folding Problem" is considered to be one of the "Great Challenges of Computer Science" and prediction of disordered protein is an important part of the protein folding problem. Machine learning models can predict the disordered structure of protein based on its characteristic of "learning from examples". Among many machine learning models, we investigate the possibility of multilayer perceptron (MLP) as the predictor of protein disorder. The investigation includes a single hidden layer MLP, multi hidden layer MLP and the hierarchical structure of MLP. Also, the target node cost function which deals with imbalanced data is used as training criteria of MLPs. Based on the investigation results, we insist that MLP should have deep architectures for performance improvement of protein disorder prediction.
Development of a FRET-based High-Throughput Screening System for the Discovery of Hsp90 Inhibitors
Oh, Sang-Mi,Ko, Yeon-Jin,Lee, Han-Jae,Kim, Jong-Hoon,Chung, Young-Sun,Park, Seung-Bum Korean Chemical Society 2011 Bulletin of the Korean Chemical Society Vol.32 No.9
A FRET-based high-throughput screening system was developed for the discovery of competitive smallmolecule Hsp90 inhibitors. The biarsenical fluorescein derivative FlAsH and dabcyl-conjugated Hsp90 inhibitor GM were employed as the FRET donor and quencher, respectively. The spatial proximity perturbation between FlAsH-labeled Hsp90N and GM-dabcyl upon treatment of a small molecule led to changes in the FRET-induced fluorescence, monitored in a high-throughput fashion.
CHARACTERIZATION OF MAGNETIZATION BEHAVIOR IN Co / Pd PERPENDICULAR ANISOTROPIC MULTILAYERS
Hoon-Sang Oh,Seung-Ki Joo 한국자기학회 1995 韓國磁氣學會誌 Vol.5 No.5
Magnetization behavior of sputter-deposited Co/Pd multilayers were characterized, and it has been found that even when the multilavers are sputtered at low pressure(100 mTorr), the coercivity of the multilayers can be increased to large extent without noticeable change of saturation magnetization by increasing the deposition pressure of Pd underlayer. It turned out that the surface topology of Pd underlayer gets rough as deposition pressure increases, which consequently affects the magnetization reversal mode of Co/Pd multilayers from domain wall motion to magnetic spin rotation. The enhancement of coercivity is attributed to tile domain wall pinning effect which is connected with the surface roughness of Pd underlayer-on which Co/Pd multilayers grow.
Acute Pancreatitis Due to a Duodenal Ulcer
Sung Ik Pyeon,Jong Ho Hwang,Yong Tae Kim,Ban Seok Lee,Sang Ho Lee,Jae Nam Lee,Jae Hoon Cheong,Kong Jin Oh 대한소화기내시경학회 2014 Clinical Endoscopy Vol.47 No.6
Duodenal ulcers and acute pancreatitis are two of the most commonly encountered gastrointestinal diseases among the general population. However, duodenal ulcer-induced pancreatitis is very rarely reported worldwide. This report elaborates on a distinct medical treatment that contributes to partial or complete treatment of acute pancreatitis induced by a duodenal ulcer scar.
( Sang Hoon Ahn ),( Won Kim ),( Young Kul Jung ),( Jin Mo Yang ),( Jae Young Jang ),( Yong Oh Kweon ),( Yong Kyun Cho ),( Yoon Jun Kim ),( Gun Young Hong ),( Dong Joon Kim ),( Soon Ho Um ),( Joo Hyun 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Besifovir is an acyclic nucleotide phosphonate known to be effective in hepatitis B virus (HBV) DNA suppression for both treatment- naïve and lamivudine-resistant chronic HBV infection in preliminary studies. We assessed the safety and efficacy of besifovir comparing with tenofovir in treatment-naïve chronic hepatitis B patients. Methods: A total of 187 patients were randomly received besifovir dipivoxil 150mg or tenofovir disoproxil fumarate 300mg. Eligible subjects were patients with chronic HBV infection. We measured the proportion of patients who had HBV DNA less than 69 IU/mL at week 48 as the primary efficacy endpoint. Key secondary endpoints were histological response (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis), serum HBV DNA reduction, and liver function tests. Also, bone mineral density (BMD) and renal parameters were evaluated. Results: The proportion of patients who achieved primary endpoint of HBV DNA (< 69 IU/mL) at week 48 were 85.33% and 88.75% among those who received besifovir and tenofovir, respectively. Besifovir was shown to be non-inferior to tenofovir (lower limit of 95% CI for the treatment difference =-0.14). Histological improvement of 29 patients who underwent liver biopsy was evaluated, and we found that significantly more patients treated with besifovir had improved histological response than those treated with tenofovir (77.78% vs. 36.36%, p=0.0482). There was no difference in intrahepatic cccDNA reduction between the two groups (p=0.35). None of the patients had resistant to mutations or increase in serum creatinine >0.5mg/dL from baseline. Patients who received besifovir had smaller decrease in BMD during 48 weeks than that of tenofovir (besifovir -0.02±0.44, tenofovir -0.10±0.86, p=0.0248). There was no adverse drug reaction leading the patients to withdrawal. Conclusions: This phase 3 study demonstrated that besifovir had comparable efficacy and safety profile to tenofovir in the treatment of treatment-naïve chronic hepatitis B patients. Besifovir showed better profile than tenofovir in both histological response and bone loss. An open-label extension study is ongoing with besifovir to investigate long-term efficacy and safety.